Rafael Holdings announces topline Phase 3 TransportNPC study results
Rafael Holdings (RFL RFL-WT) announced topline results from its pivotal Phase 3 TransportNPC™ study of Trappsol® Cyclo™ in Niemann-Pick disease type C (NPC).
Rafael Holdings (RFL RFL-WT) announced topline results from its pivotal Phase 3 TransportNPC™ study of Trappsol® Cyclo™ in Niemann-Pick disease type C (NPC).